Journal Article

Evaluation of liver enzyme elevations and hepatotoxicity in patients treated with checkpoint inhibitor immunotherapy

Cunningham, Morven, Spreafico, Anna, Kanjanapan, Yada, Feld, Jordan J., Bedard, Philippe L., Ross, Kendra, Butler, Marcus, Hansen, Bettina, Cerocchi, Orlando, Iafolla, Marco, Siu, Lillian L.

2021

Overview

Immune checkpoint inhibitors (ICI) are increasingly used in cancer therapy. Elevated liver enzymes frequently occur in patients treated with ICI but evaluation is poorly described. We sought to better understand causes of liver enzyme elevation, investigation and management. Patients treated with anti-PD-1, PDL-1 or CTLA-4 therapy in Phase I/II clinical trials between August 2012 and December 2018 were included. Clinical records of patients with significant liver enzyme elevations were retrospectively reviewed. Of 470 ICI-treated patients, liver enzyme elevation occurred in 102 (21.6%), attributed to disease progression (56; 54.9%), other drugs/toxins (7; 6.9%), other causes (22; 21.6%) and ICI immunotoxicity (17; 16.7%; 3.6% of total cohort). Immunotoxicity was associated with higher peak ALT than other causes of enzyme elevation (N = 17; M = 217, 95% CI 145-324 for immunotoxicity, N = 103; M = 74, 95% CI 59-92 for other causes; ratio of means 0.34, 95% CI 0.19-0.60, p = <0.001) and higher ALT:AST ratio (M = 1.27, 95% CI 0.78-2.06 for immunotoxicity, M = 0.69, 95% CI 0.59-0.80 for other causes, ratio of means 0.54, 95% CI 0.36-0.82, p = 0.004). Immunotoxicity was more often seen in patients with prior CPI exposure (41.2% of immunotoxicity vs 15.9% of patients without, p = 0.01), anti-CTLA-4 -containing ICI treatments (29.4% of immunotoxicity vs 6.8% of patients without, p = <0.001) and other organ immunotoxicity (76.5% of immunotoxicity vs 19.2% of patients without, p = <0.001). Cause for enzyme elevation was established in most patients after non-invasive investigation. Liver biopsy was reserved for four patients with atypical treatment response. Liver enzyme elevation is common in patients receiving ICI, but often has a cause other than immunotoxicity. A biochemical signature with higher ALT and ALT/AST ratio, a history of prior ICI exposure and other organ immunotoxicities may help to identify patients at a higher likelihood of immunotoxicity. Liver biopsy can be safely deferred in most patients. We propose an approach to diagnostic evaluation in patients with liver enzyme elevations following ICI exposure.

• Publisher: Public Library of Science,Public Library of Science (PLoS)
• Subject: Alanine / Alanine transaminase / Alkaline phosphatase / Analysis / Apoptosis / Aspartate aminotransferase / Bilirubin / Biology and Life Sciences / Cancer / Care and treatment / Clinical Trials, Phase I as Topic / Clinical Trials, Phase II as Topic / Cohort Studies / Complications and side effects / CTLA-4 protein / Cytotoxicity / Editing / Enzymes / Evaluation / Female / Follow-Up Studies / Hazard assessment / Health care networks / Hepatotoxicity / Humans / Immune checkpoint inhibitors / Immune Checkpoint Inhibitors - adverse effects / Immune response / Immunology / Immunotherapy / Immunotoxicity / Inhibitors / Liver / Liver - drug effects / Liver - enzymology / Liver diseases / Lymphocytes / Lymphocytes T / Male / Medicine and Health Sciences / Membrane Transport Proteins - immunology / Methodology / Middle Aged / Neoplasms - drug therapy / Neoplasms - enzymology / Patient outcomes / Patients / PD-1 protein / PD-L1 protein / Phosphatase / Proteins / Regression analysis / Retrospective Studies / Tumors